AUPH Aurinia Pharmaceuticals Inc

CUSIP No.                       __05156V102___  _

13G

Page                       ____ 2 ___            of                      ____ 6 _____

 

Item 1(a).

Name of Issuer :

Aurinia Pharmaceuticals Inc.

Item 1(b).

Address of Issuer’s Principal Executive Offices :

#1203-4464 Markham Street, Victoria, British Columbia V8Z7X8, Canada.

Item 2(a).

Names of Persons Filing :

This statement is being filed by venBio Global Strategic Fund, L.P. (“the Fund”); venBio Global Strategic GP, L.P. (“the General Partner”), which is the sole general partner of the Fund; venBio Global Strategic GP, Ltd. (the “GP Ltd.”), which is the sole general partner of the General Partner; Robert Adelman (“Adelman”), a director of the GP Ltd.; Corey Goodman (“Goodman” and, together with Adelman, the “Directors”), a director of the GP Ltd. The Fund, the General Partner, the GP Ltd. and the Directors are sometimes referred to collectively herein as the “Reporting Persons”.

Item 2(b).

Address of Principal Business Office or, if None, Residence :

The address of the principal business office of each Reporting Person is c/o venBio Partners, LLC, 1700 Owens Street, Suite 595, San Francisco, CA 94158.

Item 2(c).

Citizenship :

Each of the Fund and the General Partner is a Cayman Islands exempted limited partnership.  The GP Ltd. is a Cayman Islands exempted company.  Each of the Directors is a United States citizen.

Item 2(d).

Title of Class of Securities :

Common Shares, no par value (“Common Stock”).

Item 2(e).

CUSIP Number :

05156V102 .

Item 3.

If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

Not applicable.

Item 4.

Ownership .

Not applicable.

Item 5.

Ownership of Five Percent or Less of a Class .

Each Reporting Person has ceased to beneficially own five percent (5%) or more of the Issuer’s outstanding Common Stock.

 

CUSIP No.                       05156V102

13G

Page                       _____ 3 ____            of                      ______ 6 ______

 

Material to be Filed as Exhibits .

Exhibit 1

– Agreement regarding filing of joint Schedule 13G.

Exhibit 2

– Power of Attorney regarding filings under the Securities Exchange Act of 1934, as amended.

 

CUSIP No.                       05156V102

13G

Page                      ____ 4 _____            of                     _____ 6_____

 

SIGNATURE

After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Date:            July 5, 2017

 

 

 

 

 

 

 

 

 

This Schedule 13G was executed by David Pezeshki on behalf of the individual listed above pursuant to a Power of Attorney, a copy of which is attached as Exhibit 2.

 

 

---